Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Hepatocellular 6 Colorectal Neoplasms 4 Neoplasms 3 Uterine Cervical Neoplasms 2 Neoplasm Metastasis 2 Liver Neoplasms 2 Solid Tumors 1 Sarcoma 1 Rectal Neoplasms 1 Pyloric Stenosis, Hypertrophic 1 Ovarian Neoplasms 1 Gastrointestinal Neoplasms 1 Endometrial Adenocarcinoma 1 Colonic Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1 Advanced Hepatocellular Carcinoma (HCC) 1 Adenocarcinoma Of Esophagus 1 Acrocephalosyndactylia 1

Interventions

Sunitinib 145 Nivolumab 144 pembrolizumab 132 Sorafenib 84 Bevacizumab 77 Everolimus 74 cabozantinib 71 pazopanib 65 Axitinib 65 Ipilimumab 62 aldesleukin 52 Magnetic Resonance Spectroscopy 45 Cyclophosphamide 40 Interleukin-2 38 lenvatinib 37 Specimen Handling 36 Radiosurgery 36 Interferon-alpha 32 atezolizumab 30 temsirolimus 27 belzutifan 24 Gemcitabine 23 fludarabine phosphate 22 avelumab 22 Radiotherapy 19 Interferon alpha-2 19 Biopsy 18 fludarabine 17 durvalumab 17 Nephrectomy 17

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Renal Cell × brivanib × Clear all

NCT01253668 2021-04-13

Brivanib Metastatic Renal Cell Carcinoma

Abramson Cancer Center at Penn Medicine

Phase 2 Terminated

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡